达嘉维康：持续看好中药新药、创新药 密切关注并探索布局可行性

Core Viewpoint - Dajia Weikang (301126) is optimistic about the development potential and market prospects of traditional Chinese medicine new drugs and innovative drugs, and is actively exploring feasible layouts to improve its industrial chain [1] Group 1 - The subsidiary Tianji Caotang is conducting technical reviews for the in-development product Sacubitril/Valsartan Sodium Tablets [1] - The company is preparing to submit a declaration for Ezetimibe/Atorvastatin Calcium Tablets [1] - The company is closely monitoring and exploring the feasibility of its layout in the industry [1]